Anne H Robinson

US Patent:

20220273651, Sep 1, 2022

Filed:

Apr 28, 2022

Appl. No.:

17/732070

Inventors:

- North Chicago IL, US
Roopal B. Thakkar - Lake Forest IL, US
Steven Jungerwirth - Glencoe IL, US
Ana Paula Machado De Lacerda - Evanston IL, US
Anne M. Robinson - Highland IN, US
Ahmed A. Othman - Libertyville IL, US
Ben Klünder - Ludwigshafen, DE

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 31/4985
A61K 31/495
A61P 1/00
A61K 9/00
A61K 9/48

Abstract:

The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.

US Patent:

20190046527, Feb 14, 2019

Filed:

Mar 9, 2018

Appl. No.:

15/917013

Inventors:

- North Chicago IL, US
Steven JUNGERWIRTH - Glencoe IL, US
Ana Paula Machado de LACERDA - Evanston IL, US
Anne M. ROBINSON - Highland IN, US
Jose Jeffrey V. ENEJOSA - Evanston IL, US
Aileen L. PANGAN - LaGrange IL, US
Ahmed A. OTHMAN - Waukegan IL, US
Ben KLÜNDER - Ludwigshafen, DE

International Classification:

A61K 31/4985
A61P 1/00
A61K 9/48
A61K 9/00

Abstract:

The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.